Figures computed from official regulatory filings — .
Analysttarget 80 USD (+21999%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 68.82% · institutions 1.42% · short 0.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ENLIVEN MARKETING TECHNOLOGIES CORP only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
12 buys50 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Murray Michael Anthony | Sell | $156.8K | SEC | ||
| Spanfeller James |
| AwardD (derivative) |
| $15K |
| SEC |
| WEATHERSON HARVEY D | AwardD (derivative) | $15K | SEC |
| RANEY DENNIS Rtrack record | AwardD (derivative) | $15K | SEC |
| JONES SAMUEL | AwardD (derivative) | $15K | SEC |
| Vogt Patrick | AwardD (derivative) | $350K | SEC |
| DUIGNAN CHRISTOPHER C | AwardD (derivative) | $70K | SEC |
| Vogt Patrick | AwardD (derivative) | $280K | SEC |
| Graf Andrew J | AwardD (derivative) | $87.5K | SEC |
| Graf Andrew J | OtherD (derivative) | $41.3K | SEC |
| DUIGNAN CHRISTOPHER C | OtherD (derivative) | $33K | SEC |
| DUIGNAN CHRISTOPHER C | AwardD (derivative) | $33K | SEC |
| Graf Andrew J | AwardD (derivative) | $41.3K | SEC |
| JONES SAMUEL | AwardD (derivative) | $8.6K | SEC |
| RANEY DENNIS Rtrack record | AwardD (derivative) | $8.6K | SEC |
| DUFF STEPHEN M | AwardD (derivative) | $8.6K | SEC |
| WEATHERSON HARVEY D | AwardD (derivative) | $8.6K | SEC |
| Graf Andrew J | AwardD (derivative) | $39K | SEC |
| DUIGNAN CHRISTOPHER C | AwardD (derivative) | $39K | Unusual size | SEC |
| DUIGNAN CHRISTOPHER C | AwardD (derivative) | $81K | SEC |
| Graf Andrew J | AwardD (derivative) | $162K | SEC |
| MITCHELL WILLIAM HAYWARD | AwardD (derivative) | $162K | SEC |
| CRABBE JAMES | AwardD (derivative) | $12.2K | SEC |
| RANEY DENNIS Rtrack record | AwardD (derivative) | $12.2K | SEC |
| BENNETT THOMAS | AwardD (derivative) | $12.2K | SEC |